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Abstract 
Recently, we carried out a research on new liposomal systems prepared by using in 
their composition a few penetration enhancers which differ for chemical structure and 
physicochemical properties. The Penetration Enhancer-containing Vesicles (PEVs) were 
prepared by using soy lecithin and different amounts of three penetration enhancers, 2-(2-
ethoxyethoxy) ethanol (Transcutol®), capryl-caproyl macrogol 8-glyceride (Labrasol®), and 
cineole .To study the influence of the PEVs on (trans)dermal delivery of minoxidil, in vitro 
diffusion experiments were performed through new born pig skin and the results were 
compared with that obtained applying the vesicular system without enhancer (control) after 
pretreatment of the skin with the various enhancers.  
In this study Fourier Transform Infrared Spectroscopy (FTIR), Attenuated Total 
Reflectance FTIR (ATR-FTIR) and FTIR imaging were used to evaluate the effective 
penetration of minoxidil in the skin layers and to discover the influence of the enhancer on the 
drug topical delivery. These analytical studies allowed us to characterize the drug 
formulations and to evaluate the vesicle distribution into the skin. Recorded spectra confirmed 
that the vesicle formulations  with penetration enhancers promoted drug deposition into the 
skin. 
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Introduction  
The skin represents one of the most attractive sites for non-invasive administration of therapeutic 
agents, but the main obstacle to dermal and transdermal drug delivery is the barrier formed by the 
stratum corneum (SC) due to its brick and mortar-like structure that provides resistance to drug 
penetration. In order to obtain an enhanced drug delivery through the skin, topical formulations able 
to produce a temporary and reversible reduction of the SC resistance to diffusion of molecules are 
required. 
Minoxidil (MX) is the most widely used drug for the topical treatment of androgenetic alopecia, an 
androgen dependent process, that is the mainly cause of hair loss in men and women with a genetic 
predisposition. The mechanism by which MX, topically applied, stimulates hair growth is not 
clearly understood and several different hypothesis have been reported from the 1980s onwards. 
Recently, has been reported that hair follicle dermal papilla cells represent the main target site for 
MX, which has a direct effect on the proliferation and apoptosis of these cells. The MX maximum 
effect is evident after 5 months of therapy, but it is not permanent. The treatment suspension causes 
an acceleration of hair loss 4-6 months. It is possible to find MX formulations containing ethanol, 
propylene glycol and water [1, 2]. It is recommended twice a day application, but the chronic use is 
responsible of adverse effect, such as irritation, burning, itching [3], that reduce the compliance of 
users. To reduce side effects, and improve the therapeutic efficiency, there is the need to develop 
novel formulations for topical application. To increase MX accumulation in the skin layers in recent 
years different vesicular systems have been investigated. Lipid vesicles are reported to enhance 
topical drug delivery, with a reduction of the dose applied [4-12].  
Recent approaches in modulating drug delivery through the skin led to the development of novel 
vesicular carriers with elastic properties called Transfersomes®. These vesicles consist of 
phospholipids and an edge activator, that destabilizes the lipid bilayer and increases its 
deformability. The edge activator is a single chain surfactant molecule, which could be replaced 
with chemical penetration enhancers [10, 13]. 
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In the attempt to find new vesicular formulations able to optimize MX cutaneous delivery, in 
a previous work we prepared and characterized new liposomal systems prepared by using in 
their composition a few penetration enhancers (PEs) which differ for chemical structure and 
physicochemical properties [14]. The ability of the different penetration enhancers to produce 
elastic vesicles with soy lecithin and the influence of the Penetration Enhancer-containing 
Vesicles (PEVs) on (trans)dermal delivery of minoxidil were evaluated [15]. 
In this work so-called PEVs were prepared by using soy lecithin and three penetration 
enhancers, 2-(2-ethoxyethoxy)ethanol (Transcutol®), capryl-caproyl macrogol 8-glyceride 
(Labrasol®), and cineole and Fourier Transform Infrared Spectroscopy (FTIR), Attenuated 
Total Reflectance FTIR (ATR-FTIR) and FTIR imaging were used to evaluate the effective 
penetration of minoxidil in the skin layer and to discover the influence of the enhancer on this 
topical delivery. 
Over the last decade, ATR-FTIR technique has been used to characterize the structure and the 
properties of the stratum corneum and for the detection of drugs penetration after application on 
skin [16, 17]. ATR-FTIR spectroscopy is also instructive with respect to the structural and 
conformational status of stratum corneum components and their modification after application of 
enhancers [18]. This technique has been extensively used to rapidly and noninvasively quantify in 
vivo the uptake of a chemical into the outermost, and least permeable, layer of human skin (the 
stratum corneum) [19-23]. Finally, it has also been used to understand the modifications of the lipid 
organization within the stratum corneum after application of different vehicles and to correlate this 
modification with the percutaneous penetration data [24, 25]. 
In this study Fourier transform infrared spectroscopy (FTIR), ATR-FTIR and FTIR imaging were 
used to evaluate the effective penetration of MX in the skin layer and to discover the influence of 
the enhancer on this topical delivery. The aim of this work was to investigate any change in the IR 
spectra of the skin after (i) pretreatment with penetration enhancers and subsequent application of 
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MX liposomal dispersion and (ii) treatment with MX PEVs, to evaluate the effective penetration of 
the drug in the skin layers.  
 
Materials and methods 
Materials 
Soy lecithin (SL) was obtained from Galeno (Potenza, Italy). Minoxidil (MX) (MW 209.25, 99% 
purity) was purchased from Farma Labor (Bari, Italy). Dicetylphosphate (DCP), cineole (Cin), were 
purchased from Aldrich (Milan, Italy). 2-(2-ethoxyethoxy)ethanol (Transcutol®, Tcr) and capryl-
caproyl macrogol 8-glyceride (Labrasol® Lb) were a gift from Gattefossè, (Saint Priest, France). 
All the products and solvents were of analytical grade. 
 
HPLC method 
MX detection was performed at 231nm using a high performance liquid chromatograph 
(HPLC) Alliance 2690 (Waters), equipped with a photodiode array detector and a computer 
integrating apparatus (Millennium 32). The column was a Nova-Pack C18 (60 Ǻ, 4 µm) 
HPLC cartridge (Waters). The mobile phase was a mixture of methanol and water (80:20, 
v/v). The sample volume injected was 50 µl. The flow rate was 2.2 ml/min. Retention time of 
MX was 1.4 min. The detection limit was 10 ng/ml. For concentrations in the range 0-50 
µg/ml a good linearity was obtained (R2=0.998; P‹0.001). 
 
Vesicle preparation and characterization 
Dehydrated-rehydrated vesicles (DRV) were prepared according to previously described methods 
[15].SL (60mg/ml), DCP (5.4 mg/ml), one PE (20 mg/ml) and MX (50mg/ml) were dissolved in 
chloroform. Then, lipid-drug mixture was deposited as a thin film in a round-bottom flask by roto-
evaporating (Rotavapor Büchi R110, Switzerland) the chloroform under vacuum, which was 
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applied for one hour to ensure total removal of solvent trace. The film was hydrated with distilled 
water under mechanical stirring at room temperature. Vesicle suspension was sonicated in a 
Soniprep 150 (MSE Crowley apparatus, Beckenham, UK) in 25 cycles of 10 seconds “on” and 10 
seconds “off”. Liposomal dispersions, were freezed at –20°C for 12 hours and then freeze-dried 
overnight using a Criotecnica freeze-drier apparatus (MM Cota Company, Roma, Italy) with 760 
mmHg operative pressure at 80°C. Vesicle were stored at 25 °C for 30 days and successively 
vesicles were reconstituted by controlled rehydration in distilled water and mechanically shaken by 
a vortex (Velp scientifica, Italy) for 10 minutes. Each vesicle suspension was purified from non-
incorporated drug by exhaustive dialysis for 4h in distilled water at 5°C using Spectra-Por® 
membranes (12-14 kDa MW cut-off, 3nm pore size; Spectrum Laboratorie Inc., USA).  
Incorporation efficiency (E%), expressed as the percentage of the drug amount initially used, was 
determined by high performance liquid chromatography (HPLC) after disruption of purified 
vesicles with a 0.025% Triton X-100 solution. Minoxidil content was quantified at 231 nm using a 
chromatograph Alliance 2690 (Waters, Italy), equipped with a photodiode array detector. The 
column was a Novo-Pack C18 (Waters, Italy) and the mobile phase was a mixture of methanol and 
water (80:20 v/v) delivered at a flow rate of 2.2 ml/min. The MX retention time was 1.4 min. 
 
In vitro skin penetration studies and skin pre-treatment.  
Before use, the lyophilised MX loading vesicles with and without enhancer (control) were re-
hydrated with distilled water and mechanically shaken until a milky suspension was obtained. In 
vitro skin penetration and permeation studies were performed using vertical diffusion Franz cells 
with an effective diffusion area of 0.785 cm2. New born pig skin specimens were sandwiched 
securely between donor and receptor compartments, with the epidermis side facing the donor 
compartment. One-day-old Goland–Pietrain hybrid pigs (1.2 kg) were obtained from a local 
slaughterhouse. The receptor compartment was filled with 5.5 ml of hydroalcoholic solution 
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(water/ethanol 1/1) which was continuously stirred with a small magnetic bar and thermostated at 
37°±1 °C throughout the experiments. 100 µl of either MX entrapped vesicle with penetration 
enhancers or liposomal formulation without enhancer (control group) were placed onto the skin 
surface The receiving solution was withdrawn at regular intervals of 2 hours up to 8 hours, and 
replaced with an equivalent volume of hydro alcoholic solution to ensure sink conditions. 
After 8 hours, the skin surface of specimens was washed 10 times with 1 ml of distilled water then 
dried with filter paper. The stratum corneum (SC) was removed by striping with an adhesive tape 
Tesa® AG (Hamburg Germany). A piece of the adhesive tape was firmly pressed on the skin surface 
and rapidly pulled off with one fluent stroke. Ten stripping procedures were consecutively 
performed. The epidermis was separated from the dermis with a surgical sterile scalpel. The 10 tape 
strips, epidermis and dermis, were placed each in a vial with 3 ml of methanol and then sonicated 
for four minutes in order to extract the drug. The tape and tissue suspension were centrifuged for 10 
minutes at 10000 rpm, then the supernatants were filtered and assayed for their MX content by 
HPLC as described previously. 
During pre-treatment studies, 100 µl of solution of each penetration enhancer (at the same amount 
used in the PEVs formulations) was placed in the donor compartment of the diffusion cell. After 
incubation, skin surface was washed with distilled water and MX loading liposomes were placed on 
the skin samples. Then, the in vitro study was carried out for 8 hours as described above.  
 
Isolation of SC and viable epidermis. 
After the in vitro permeation and penetration studies epidermis was separated from the dermis by 
immersion of full thickness skin in a 60°C water bath for 2 minutes. It led possible to peel cycles of 
epidermis from the underlying tissue 
The resulting sheets were rinsed with ultrapure water, dried at room temperature and stored in open 
boxes until used. 
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Preparation of samples 
Before physical analysis, lyophilized MXloading vesicles were re-hydrated with distilled water and 
mechanically shaken until an homogeneous dispersion was obtained.  
For the spectroscopy study the epidermis specimens were compressed applying a strength of 3-4 ton 
using an hydraulic press to obtain a thinner and homogeneous sample. 
 
Fourier transform infrared spectroscopy (FT-IR). 
Solid samples were milled with potassium bromide (KBr) (1/100) and pressed in a hydraulic press 
to small tablets. The FT-IR spectra were recorded on a Spectrum One FT-IR (Perkin Elmer) 
spectrometer equipped with  a Multiscope (Perkin Elmer) microscopy. Each spectrum in a range of 
4000 to 450 cm−1 was derived from 8 signal-averaged scans collected at a spectral resolution of 4 
cm−1.  
Liquid samples were analyzed placing a drop of the sample between plates of sodium chloride; 
analysis of data was carried in the range from 4000 to 600 cm−1. For each spectrum, 4 
interferograms were averaged at a spectral resolution of 4 cm−1.  
Skin samples were analyzed using BaF2 plates using Attenuated Total Reflectance FT-IR (ATR-FT-
IR) tecnique. Each spectrum was derived from 128 signal-averaged scans collected at a spectral 
resolution of 4-cm−1 The spectral window from 4000 to 700 cm−1 was chosen for identification. 
 
FT-IR imaging 
The spectra were collected using an Infrared Multichannel Viewer IMV-4000 (Jasco). Data were 
analysed using the software package Data Manager version 2 (Perkin Elmer). Each spectrum in a 
range of 4000 to 750 cm−1 was derived from 64 signal-averaged scans collected at a  
spectral resolution of 16-cm−1, 32-mm/s scan speed.  
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Statistical analysis of data 
Data analysis was carried out with the software package Microsoft Excel, version 2003. 
Results are expressed as mean ± standard deviation. One way analysis of variance (ANOVA) 
was used to substantiate statistical differences between groups, while Student’s t-test was used 
for comparison between two samples. We used P<0.05 as a minimal level of significance.  
 
 
Results and discussion 
In a previous work [15], liposomal vesicles prepared with penetration enhancers (PEVs) were 
characterized and their influence on MX accumulation was evaluated. All PEV formulations were 
able to incorporated a good amount of MX. Indeed, E% ranged from ≈60 % (PEVs with labrasol 
and transcutol) to ≈70% (PEVs with cineole). In particular, we demonstrated that the introduction of 
PE in the vesicular formulation led to deformable vesicles able to penetrate deeply in the skin with a 
formation of a drug depot.  
In order to evaluate the effect of PEV incorporation on minoxidil skin (trans)dermal delivery, we 
carried out in vitro permeation study by applying MX loaded PEV formulations and conventional 
liposomes with the same lipid composition, but without PE, as control. All the experiments were 
carried out on the whole skin and in occlusive conditions. The choice of this model enabled us to 
perform measurements of the permeated as well as of the accumulated drug into the skin layers. To 
ascertain the role of the PEVs in the drug cutaneous delivery, permeation experiments were also 
carried out by pre-treating the skin with solutions of “free” PE and then applying MX loading 
liposomes. In table 1 the results of the experiments are reported. 
The amount of MX detected in the skin layers, after PEVs treatment, was higher than that obtained 
placing the control formulation on the pre-treated skin specimens. Except for experiments with 
Transcutol®, the pre-treatment led to a reduction of the percentage of MX accumulated in the skin 
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in comparison with results obtained when the chemical enhancer was a vesicle component (i.e. 
PEVs). By contrast, using Transcutol® as enhancer, the percentage of drug accumulated in the 
stratum corneum was approximately the double. Moreover, the same enhancer was responsible for 
the least transdermal permeation through the skin. The formation of the drug depot is due to 
swelling of the stratum corneum intercellular lipids caused by Transcutol®. Inclusion of chemical 
enhancers in a liposomal formulation is capable of improving accumulation of minoxidil in the 
stratum corneum: that is due to the fact that these elastic vesicles do not travel beyond this skin 
layer and the permeation into the deep layers requires both drug release from the vesicles and its 
diffusion. 
Then, FTIR spectroscopy was used to analyse the vesicular formulations and to study the diffusion 
and distribution of MX in the skin. 
The first step of the study was to evaluate if the drug identification in the colloidal system was 
possible. MX, each liposome component and vesicular dispersion were analysed by FTIR. 
A vesicular dispersion containing only soy lecithin and dicetylphosphate was also prepared and the 
FTIR spectrum was compared with those of free minoxidil and minoxidil containing vesicular 
systems. As shown in Fig 1, the MX  stretchings corresponding to NH2 (3451, 3411 cm-1), =N-H 
(3371 cm-1), C=C and C=N (1644,1611, 1555  cm-1), pyrimidine N-oxide  (1234  cm-1) and the 
system bands in the fingerprint region (874, 859, 849, 822 and at 756 cm- 1) are clearly visible in the 
spectrum of the MX containing liposomes.  
FTIR analysis were then carried out on skin specimens which had been pre-treated with the 
enhancers used in PEV formulations and then treated with the PEVs or the control for an 8h in vitro 
permeation experiment. Before the analysis, the epidermis layer was compressed with an hydraulic 
press to obtain samples more homogeneous and with the same thickness, to avoid saturated signals, 
thus, allowing a comparative analysis of absorption band intensities. After the compression 
procedure, the skin samples showed different reactions to the hydraulic pressure: the pre-treated 
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specimens tended to break, while those treated with PEVs were more elastic and underwent a 
deformation without any rupture. 
To verify the MX penetration into the skin, we used the spectral window between 900 and 700 cm-1; 
in the other spectral regions, the SC absorption bands overlapped those of the vesicular components. 
FTIR spectra of the samples of PEVs treated skin showed well-defined absorption bands in the 
fingerprint region, a fact that may be attributed to the MX penetration into the skin. Although the 
enhancers analyzed separately showed absorption bands in that region, the signals, due to the low 
concentrations employed, are not visible in the skin, neither pretreated nor treated with PEVs (Fig.2, 
3,4). 
FTIR analysis confirmed the topical absorption of MX: the use of the PEVs led to a topical 
accumulation of the drug higher than that obtained with the control.  
FTIR imaging spectroscopy has been shown to be a useful tool for studying molecule distribution in 
SC because it offers the possibility to obtain spatial information of the skin. FTIR images are 
formed on the basis of the contrast provided by the characteristic frequencies of a unique absorption 
band of the various components in the analyzed sample.  
To investigate the distribution of MX loaded vesicles in the skin specimens, we carried out an FTIR 
imaging study. The skin samples were pressed to thin it to an appropriate thickness. FTIR images 
allowed us to verify the uniform thickness of the skin specimens. By recording images using a 
specific marker band both for liposomes and epidermis, it is possible to obtain maps whose 
superposition gives information about the vesicle penetration into the skin layers. 
Fig.5 shows the map obtained analyzing a skin sample treated with the vesicular dispersion 
containg Labrasol®. Blue is used to report the absorption at 1735 cm-1 of the SL phosphate groups 
of MX liposomes (Fig.5a), while red represents the absorption at 1527 cm-1, associated to epidermis 
components (Fig.5b). The superposition of the two images (Fig. 5c) , confirmed a distribution of 
MX loaded vesicles in all the skin surface, and showed both vesicles adsorption and absorption.  
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Conclusion 
In the present study, we investigated by FTIR analysis the ability of vesicles containing different 
penetration enhancers to increase MX accumulation in the upper skin layers. FTIR analysis showed 
the different drug behavior in the skin after treatment with PEVs or pretreatment with penetration 
enhancers and subsequent application of the MX liposomal dispersion (control).  
Analytical results confirmed that the vesicle formulations with penetration enhancers promoted 
drug deposition in the skin compared to the control. FTIR imaging spectroscopy confirmed the 
vesicle distribution in the stratum corneum. 
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CAPTIONS OF FIGURES 
 
Fig.1:  FTIR spectra of vesicular dispersion (a),minoxidil  (b) and vesicular dispersion containing 
minoxidil (c) in the range between 4000-2600 cm-1 (A) and 2000-700 cm-1 (B) 
Fig. 2: FTIR spectra of skin sample (a), skin pretreated with Labrasol and than with liposome (b), 
skin treated with  minoxidil containing PEV (c) in the range between 4000-2600 cm-1 (A) and 2000-
700 cm-1 (B) 
Fig. 3: FTIR spectra of skin sample (a), skin pretreated with Cineole and than with liposome (b), 
skin treated with  minoxidil containing PEV (c) in the range between 4000-2600 cm-1 (A) and 2000-
700 cm-1 (B) 
Fig. 4: FTIR spectra of skin sample (a), skin pretreated with Transcutol and than with liposome (b), 
skin treated with  minoxidil containing PEV (c) in the range between 4000-2600 cm-1 (A) and 2000-
700 cm-1 (B). 
Fig 5: Absorption of the phosphate groups of soy lecithin at 1735 cm-1 (a); represent the absorption 
at 1527 cm-1, associated to epidermis components (b); superposition of a and b (c) 
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Table 1. Results of in vitro permeation study after treatment of pig skin with PEV suspensions or 
after pre-treatment of pigskin with penetration enhancer solutions followed by treatment with 
conventional MX loaded liposomes (control): percentage of MX accumulated into and delivered 
through the skin at the end of the experiments. Each data is the mean ± standard deviation of at least 
six experimental determinations. 
 
 
Formulation 
Dose minoxidil  (%) 
SC Epidermis Dermis Receptor fluid 
Control 4.02 ± 0.15 2.33 ± 0.04 0.08 ± 0.01 n.d. 
PEV (labrasol) 11.07 ± 0.77 8.95 ± 1.07 0.02 ± 0.01 n.d. 
PEV (transcutol) 4.99 ± 0.42* 2.82 ± 0.38* 0.06 ± 0.01 n.d. 
PEV (cineole) 12.85 ± 1.07 4.04 ± 0.09 0.09 ± 0.02 n.d. 
Labrasol + control 6.19 ± 1.46 2.17 ± 0.33 0.04 ± 0.004 0.41 ± 0.18 
Transcutol + control 8.86 ± 0.71 2.88 ± 0.28 0.17 ± 0.002 0.28 ± 0.17 
Cineole + control 7.01 ± 2.13 3.18 ± 0.65 0.004 ± 0.001 4.71 ± 1.09 
*p< 0.05 in comparison with control (n=9) 
n.d. not determined 
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